What's fueling the biotech engine-2011 to 2012

Nature Biotechnology

Volumn 30, Issue 12, 2012, Pages 1191-1197

  Aggarwal, Saurabh ^a  

^a Novel Health Strategies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AFLIBERCEPT; BELATACEPT; BELIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BRENTUXIMAB VEDOTIN; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DEGLUDEC; DOCETAXEL; ELYESO; ETANERCEPT; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IMIGLUCERASE; INFLIXIMAB; INSULIN GLARGINE; INSULIN LISPRO; IPILIMUMAB; IRINOTECAN; LIRAGLUTIDE; LIXISENATIDE; PEGINESATIDE; RANIBIZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TALIGLUCERASE ALFA; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELAGLUCERASE ALFA; XGEVZ;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; DRUG COST; DRUG MARKETING; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BIOTECHNOLOGY; BLOOD COAGULATION FACTORS; COMMERCE; CYTOKINES; ENZYMES; GROWTH SUBSTANCES; HORMONES; HUMANS; MARKETING; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 84870949388     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2437     Document Type: Article

References (19)

1. IMS Health Top-Line Market Data.
2. Aggarwal, S. What's fueling the biotech engine-2009-2010. Nat. Biotechnol. 28, 1165-1171 (2010).
3. Aggarwal, S. What's fueling the biotech engine - 2008. Nat. Biotechnol. 27, 987-993 (2009).
4. Aggarwal, S. What's fueling the biotech engine - 2010 to 2011. Nat. Biotechnol. 29, 1083-1089 (2011).
5. Hamlin, P.A. Is maintenance rituximab now ready for PRIMA-time? Curr. Oncol. Rep. 12, 355-357 (2010).
6. Garber, K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29, 467-468 (2011).
7. Sandborn, W.J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616-624 (2012).
8. van Vollenhoven, R.F., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
9. Helwick, C. Bevacizumab beyond progression prolongs survival in metastatic colorectal cancer. The ASCO Post 3 (15 July 2012).
10. Heitz, F. et al. Bevacizumab in the treatment of ovarian cancer. Adv. Ther. 29, 723-735 (2012).
11. Bach, P.B., Saltz, L.B. and Wittes, R.E., "In cancer care, costs matters.," NY Times, 14 October 2012
12. de Claro, R.A., et al. U.S. Food and Drug Administration approval summary: Brentuximab Vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma. Clin. Cancer Res. 18, 5845-5849 (2012).
13. Zinman, B. et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377, 924-931 (2011).
14. Collins, A.J. ESRD Payment Policy Changes: The New "Bundled," Dialysis Prospective Payment System in the United States (US Renal Data System, 2012).
15. Aggarwal, S. Access, Uptake and Utilization Management of Multiple Sclerosis Products in the United States. Abstract PND72, presented at 15th Annual European Congress, November 3-7, 2012, Berlin, Germany.
16. Hayes, E. Dendreon readies for next Provenge hurdles: supply and reimbursement. The Pink Sheet Daily 71 (3 May 2010).
17. Aggarwal, S. Targeted cancer therapies. Nat. Rev. Drug Discov. 9, 427-428 (2010).
18. Polonsky, K.S. The past 200 years in diabetes. N. Engl. J. Med. 367, 1332-1340 (2012).
19. Aggarwal, S. Impact of 2009-2011 global health care reforms on pricing, access and health outcomes strategy. Podium Presentation UT2 presented at International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, June 2-6, 2012, Washington, DC, USA.